This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, C.-Y. Articles by Shih, I.-M. Search for Related Content PubMed PubMed Citation Articles by Hsu, C.-Y. Articles by Shih, I.-M.

Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas

Departments of ¹ Pathology and ² Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland; ³ Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital Taipei, Taiwan; and ⁴ Department of Pathology, National Yang-Ming University School of Medicine, Taipei, Taiwan

ABSTRACT

Purpose: Mitogen-activated protein kinase (MAPK) plays a pivotal role in signal transduction. Activation of MAPK is regulated by upstream kinases including KRAS and BRAF, which are frequently mutated in low-grade ovarian serous carcinoma. This study evaluates the expression of active MAPK in ovarian serous carcinomas, with response to treatment and survival.

Experimental Design: Expression of active MAPK was assessed by immunohistochemistry in 207 cases of ovarian serous tumors. Immunoreactivity was correlated with tumor grade, mutational status of KRAS and BRAF, in vitro drug resistance, and clinical outcome.

Result: There was a lower frequency of expression of active MAPK in high-grade ovarian serous carcinomas as compared with low-grade serous tumors, including borderline tumors and low-grade serous carcinoma (P < 0.001). Active MAPK was present in all of the 19 low-grade tumors with either KRAS or BRAF mutations as well as in 14 (41%) of 34 tumors with wild-type KRAS and BRAF in both low- and high-grade carcinomas. Expression of active MAPK alone served as a good survival indicator in the 2-year follow-up (P = 0.037) but not in the 5-year follow-up (P = 0.145). However, a combination of expression of active MAPK and in vitro sensitivity of paclitaxel significantly correlated with a better prognosis in 5-year survival rate (P = 0.048) in patients with advanced-stage high-grade serous carcinoma.

Conclusions: Active MAPK is more frequently expressed in low-grade than in high-grade ovarian serous carcinoma. Active MAPK serves as a good prognostic marker in patients with high-grade serous carcinomas.

This article has been cited by other articles:

				D. M. Gershenson, C. C. Sun, K. H. Lu, R. L. Coleman, A. K. Sood, A. Malpica, M. T. Deavers, E. G. Silva, and D. C. Bodurka Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary Obstet. Gynecol., August 1, 2006; 108(2): 361 - 368. [Abstract] [Full Text] [PDF]

				F. McPhillips, P. Mullen, K. G. MacLeod, J. M. Sewell, B. P. Monia, D. A. Cameron, J. F. Smyth, and S. P. Langdon Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells Carcinogenesis, April 1, 2006; 27(4): 729 - 739. [Abstract] [Full Text] [PDF]

				I.-M. Shih and R. J. Kurman Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges Clin. Cancer Res., October 15, 2005; 11(20): 7273 - 7279. [Abstract] [Full Text] [PDF]

				M. Kobel, G. Pohl, W. D. Schmitt, S. Hauptmann, T.-L. Wang, and I.-M. Shih Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor Am. J. Pathol., September 1, 2005; 167(3): 879 - 885. [Abstract] [Full Text] [PDF]

				G. Pohl, C.-L. Ho, R. J. Kurman, R. Bristow, T.-L. Wang, and I.-M. Shih Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations Cancer Res., March 1, 2005; 65(5): 1994 - 2000. [Abstract] [Full Text] [PDF]